Identifying Resistance Mechanisms Of Targeted BRAF Inhibitors In Metastatic Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$379,015.00
Summary
Late-stage melanoma is an aggressive skin cancer for which traditional treatment strategies such as chemotherapy are ineffective. Recently, a new class of targeted drugs (BRAF inhibitors) has become the standard of care for a subset of melanoma patients; however, long term treatment success is complicated by drug resistance. This study will identify the causes of resistance with the purpose to improve targeted drug strategies and increase survival rates for late-stage melanoma patients.
Fatty Acid Elongation: A Novel Target For Prostate Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Lipids are a class of molecules that make up cell membranes and are an important source of energy for cells. Changes in lipids occur during prostate cancer progression, most prominently in a process called fatty acid elongation, which requires enzymes called elongases. This project will seek to better understand the consequences of lipid elongation in prostate cancer cells, its potential role in therapy resistance, and whether the elongase enzymes can be targeted as new therapies.
Next-generation Glioblastoma Multiforme Therapies Based On Multistage Delivery Nanovectors
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.
Design Of Cas9 Nucleases With Reduced Basal DNA Binding And Enhanced Recombinase Activity For Human Genome Engineering
Funder
National Health and Medical Research Council
Funding Amount
$385,761.00
Summary
Cas9 has recently emerged as a transformative tool for genome engineering. The enzyme is guided by a short RNA to pair with a DNA sequence of interest and to introduce a break. This DNA break becomes a substrate for repair pathways: Non-Homologous End-Joining or Homologous Recombination. The rate of HR is typically lower, limiting the efficiency of insertion of new DNA. The project aims to determine these reasons for limited rates of HR, and to improve these rates through protein engineering.
Bioresponsive Nanocarriers For Controlled And Targeted Delivery To Efficiently Treat Inflammatory Bowel Disease (IBD)
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Despite considerable progress in treatment of Inflammatory Bowel Diseases, current treatments suffer from many disadvantages such as side effects, lack of efficacy in many patients, and development of drug dependence. Using state of art nanotechnology, novel nanoparticles will be developed to enhance the delivery to the intestine and efficacy of Budesonide (an anti-inflammatory steroid). This research promises to find safer and more effective ways to treat these diseases.
Identification Of Cancer Initiating Cells In Small-cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$364,420.00
Summary
Lung cancer is the leading cause of cancer deaths worldwide. Recently a unique mouse model of small-cell lung cancer (SCLC) has been generated that closely mimics the human disease. We will use this model to identify the cells that give rise to SCLC upon genetic alteration. Results obtained will assist in designing more effective intervention strategies aimed at overcoming initial and acquired resistance of these tumours against cytotoxic and targeted drugs.
Bifunctionalised Contrast Nanoparticles For Simultaneous Diagnosis And Treatment Of Thrombosis, Vulnerable Plaques And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$412,882.00
Summary
The aim of this project is to develop bifunctionalised contrast nanoparticles which selectively target molecular markers of cardiovascular and inflammatory diseases at various states. The nanoparticles would provide an advanced imaging technique for early diagnosis of fatty tissue build up in the vessel wall and for detecting vessel blockages. The nanoparticles would also work as drug carrier that specifically brings curative drugs to the disease site for an acute treatment simultaneously with d ....The aim of this project is to develop bifunctionalised contrast nanoparticles which selectively target molecular markers of cardiovascular and inflammatory diseases at various states. The nanoparticles would provide an advanced imaging technique for early diagnosis of fatty tissue build up in the vessel wall and for detecting vessel blockages. The nanoparticles would also work as drug carrier that specifically brings curative drugs to the disease site for an acute treatment simultaneously with diagnosis.Read moreRead less
Systematic And Sensitized Screens For Novel Genes That Regulate The Neural Differentiation Of Mouse Embryonic Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$360,634.00
Summary
Embryonic stem (ES) cells are cells in the embryo that can transform into any cell type. Genes that direct mouse ES cells to transform into cells of the nervous system will be uncovered by selecting a group of likely suspects, and disrupting the DNA sequences of these genes to see whether neural differentiation occurs normally in their absence. The effects of the gene disruptions will be examined in the developing neural system of the mouse embryo.
Identification And Characterisation Of Novel Genetic Alterations In High Risk Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$315,336.00
Summary
Acute lymphoblastic leukaemia (ALL) remains the leading cause of cancer-related death in children and young adults. The goal of this research is to identify genetic abnormalities that contribute to treatment failure in high-risk ALL. In addition to providing insights into the biologic basis of ALL, this work has the potential to result in new diagnostic tests, predict response to chemotherapy, and identify new strategies to improve the treatment outcome for ALL patients.